Masayuki Isaji - Concepedia

Author

Masayuki Isaji

Kissei Pharmaceutical (Japan)

Also Known As

Isaji, Masayuki, M ISAJI, M Isaji, M. Isaji, MASAYUKI ISAJI, Masayuki ISAJI, Masayuki Isaji

Publications

Citations

H-Index

Concepts

All Affiliations

Kissei Pharmaceutical (Japan)Shinshu University Ōtani University Utano Hospital Tokyo University of Science

About

Masayuki Isaji is an author at Kissei Pharmaceutical (Japan) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	29	1.2K
2	Health Sciences	9	9	438
3	Natural Sciences	9	9	385
4	Social Sciences	3	3	66
5	Allergy	3	3	72

Masayuki Isaji

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level Kenji Katsuno, Yoshikazu Fujimori, Yukiko Takemura, Journal of Pharmacology and Experimental Therapeutics	2006	265
Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models Yoshikazu Fujimori, Kenji Katsuno, Ikumi Nakashima, Journal of Pharmacology and Experimental Therapeutics	2008	219
SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose Shigeki Tazawa, Tokuhisa Yamato, Hideki Fujikura, Life Sciences Essential TransporterBiochemistryNatural SciencesGlycobiologyMolecular Biology	2004	202
Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells <i>in vitro</i> and angiogenesis <i>in vivo</i> Masayuki Isaji, Hiroshi Miyata, Yoshiyuki Ajisawa, British Journal of Pharmacology	1997	100
Sodium-glucose cotransporter inhibitors for diabetes. Masayuki Isaji PubMed Renal Glucose ExcretionSodium-glucose Cotransporter InhibitorsPharmacotherapyMolecular PharmacologyMetabolic Syndrome	2007	86
Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin Fumiki Oana, Hiroo Takeda, Kohichi Hayakawa, Metabolism ObesityMetabolic SyndromeNutritionZucker RatsBody Composition	2005	82
Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice Shigeru Nakano, Kenji Katsuno, Masayuki Isaji, Journal of Clinical and Experimental Hepatology ObesityMetabolic SyndromeLipid NutritionMedicineLiver Physiology	2015	82
Selective inhibition of collagen accumulation by N-(3, 4-dimethoxycinnamoyl)anthranilic acid (N-5') in granulation tissue Masayuki Isaji, Misao Nakajoh, Jun Naito Biochemical Pharmacology Tissue EngineeringMedicineGranulation TissueAnthranilic AcidWound Healing	1987	81
KGA-2727, a Novel Selective Inhibitor of a High-Affinity Sodium Glucose Cotransporter (SGLT1), Exhibits Antidiabetic Efficacy in Rodent Models Toshihide Shibazaki, Masaki Tomae, Yukiko Ishikawa-Takemura, Journal of Pharmacology and Experimental Therapeutics	2012	81
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats Yoshikazu Fujimori, Kenji Katsuno, Kazuma Ojima, European Journal of Pharmacology Metabolic SyndromeDiabetes ManagementSelective Sglt2 InhibitorBiochemistryMedicine	2009	70

Page 1